Skip to main content
Erschienen in: Journal of Gastrointestinal Cancer 4/2010

01.12.2010 | Original Research

The Surgical Treatment and Outcome for Primary Duodenal Adenocarcinoma

verfasst von: Shao-Liang Han, Jun Cheng, Hong-Zhong Zhou, Qi-Qiang Zeng, Sheng-Hong Lan

Erschienen in: Journal of Gastrointestinal Cancer | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

To investigate the early diagnosis and outcomes of surgical treatment of primary duodenal adenocarcinoma (PDAC) for curative purpose.

Method

Thirty-two PDAC patients treated surgically between February 1990 and September 2006 were analyzed retrospectively.

Results

All 32 patients underwent laparotomy including 18 (56.3%) pancreaticoduodenectomy (PD), six (18.7%) segmental resection (SR), and eight bypass procedures. And R0 resections were obtained in 22 patients; the other ten procedures were palliative. The total 1-, 3-, and 5-year survival rates in this study were 78.1% (25/32), 43.8% (14/32), and 18.8% (6/32), respectively; moreover, the 1-, 3-, and 5-year survival rates in patients with R0 resection were 100.0% (20/20), 70.0% (14/20), and 30.0% (6/20), which were significantly higher than those (41.7% = 5/12, 0%, and 0%) in patients with palliative operation (P < 0.05), respectively. Furthermore, the 5-year survival rate was 27.8% (5/18) in pancreaticoduodenectomy patients and 16.7% (1/6) in segmental resection patients, and there was no significant difference between the above two procedures (P > 0.05).

Conclusion

PD is suggested for tumor located at the first and second portion of the duodenum, and SR may be appropriate for the selected patients especially for tumors of the distal duodenum.
Literatur
1.
Zurück zum Zitat Alwmark A, Anderson A, Lasson A. Primary carcinoma of the duodenum. Ann Surg. 1980;191(1):13–8.PubMedCrossRef Alwmark A, Anderson A, Lasson A. Primary carcinoma of the duodenum. Ann Surg. 1980;191(1):13–8.PubMedCrossRef
2.
Zurück zum Zitat Egberts JH, Scharrer ML, Hinz S, Schafmayer C, Klomp HJ, Faendrich F, et al. Small bowel cancer: single-centre results over a period of 12 years. Hepatogastroenterology. 2007;54(73):129–34.PubMed Egberts JH, Scharrer ML, Hinz S, Schafmayer C, Klomp HJ, Faendrich F, et al. Small bowel cancer: single-centre results over a period of 12 years. Hepatogastroenterology. 2007;54(73):129–34.PubMed
3.
Zurück zum Zitat Hu JX, Miao XY, Zhong DW, Dai WD, Liu W, Hu W. Surgical treatment of primary duodenal adenocarcinoma. Hepatogastroenterology. 2006;53(72):858–62.PubMed Hu JX, Miao XY, Zhong DW, Dai WD, Liu W, Hu W. Surgical treatment of primary duodenal adenocarcinoma. Hepatogastroenterology. 2006;53(72):858–62.PubMed
4.
Zurück zum Zitat Shao YF, Wu TC, Shan Y, Wu JX, Wang X, Zhao P. Clinico-pathological characteristics of surgical effect on periampullary cancers: report of 631 cases. Zhonghua Yi Xue Za Zhi. 2005;85(8):510–13.PubMed Shao YF, Wu TC, Shan Y, Wu JX, Wang X, Zhao P. Clinico-pathological characteristics of surgical effect on periampullary cancers: report of 631 cases. Zhonghua Yi Xue Za Zhi. 2005;85(8):510–13.PubMed
5.
Zurück zum Zitat Ramia JM, Villar J, Palomeque A, Muffak K, Mansilla A, Garrote D, et al. Duodenal adenocarcinoma. Cir Esp. 2005;77(4):208–12.PubMedCrossRef Ramia JM, Villar J, Palomeque A, Muffak K, Mansilla A, Garrote D, et al. Duodenal adenocarcinoma. Cir Esp. 2005;77(4):208–12.PubMedCrossRef
6.
Zurück zum Zitat Saiura A, Yamamoto J, Yamaguchi T. Primary duodenal carcinoma. Gan To Kagaku Ryoho. 2004;31(3):327–30.PubMed Saiura A, Yamamoto J, Yamaguchi T. Primary duodenal carcinoma. Gan To Kagaku Ryoho. 2004;31(3):327–30.PubMed
7.
Zurück zum Zitat Liu JF, Li A, Liu Q, Zhou JS, Sun JB, Li D. Surgical treatment of 475 patients with periampullary carcinoma. Zhonghua Zhong Zhong Liu Za Zhi. 2005;27(4):251–3. Liu JF, Li A, Liu Q, Zhou JS, Sun JB, Li D. Surgical treatment of 475 patients with periampullary carcinoma. Zhonghua Zhong Zhong Liu Za Zhi. 2005;27(4):251–3.
8.
Zurück zum Zitat Kaklamanos IG, Bathe OF, Franceschi D, Camarda C, Levi J, Livingstone AS. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000;179(1):37–41.PubMedCrossRef Kaklamanos IG, Bathe OF, Franceschi D, Camarda C, Levi J, Livingstone AS. Extent of resection in the management of duodenal adenocarcinoma. Am J Surg. 2000;179(1):37–41.PubMedCrossRef
9.
Zurück zum Zitat Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg. 1992;127(5):557–60.PubMedCrossRef Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of third and fourth portions of duodenum. Favorable prognosis after resection. Arch Surg. 1992;127(5):557–60.PubMedCrossRef
10.
Zurück zum Zitat Small Intestine. In: American joint committee on cancer: manual for staging of cancer. Beahrs OH, Hason DE, Hutter RVP, Kennedy BJ, Editor. Philadelphia: JB Lippincott Co, 1992. p 69–73. Small Intestine. In: American joint committee on cancer: manual for staging of cancer. Beahrs OH, Hason DE, Hutter RVP, Kennedy BJ, Editor. Philadelphia: JB Lippincott Co, 1992. p 69–73.
11.
Zurück zum Zitat Declore R, Thomas JH, Forster J. Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg. 1993;166(12):626–31. Declore R, Thomas JH, Forster J. Improving resectability and survival in patients with primary duodenal carcinoma. Am J Surg. 1993;166(12):626–31.
12.
Zurück zum Zitat Lang H, Nadalin S, Raab R, Jahne J. Results of surgical therapy of primary adenocarcinoma of the duodenum. Chirurg. 1999;70(5):571–7.PubMedCrossRef Lang H, Nadalin S, Raab R, Jahne J. Results of surgical therapy of primary adenocarcinoma of the duodenum. Chirurg. 1999;70(5):571–7.PubMedCrossRef
13.
Zurück zum Zitat Kazerooni EA, Quint LE, Francis IR. Duodenal neoplasm: predictive value of CT for determining malignancy and tumor resectability. AJR Am J Roentgenol. 1992;159(2):303–9.PubMed Kazerooni EA, Quint LE, Francis IR. Duodenal neoplasm: predictive value of CT for determining malignancy and tumor resectability. AJR Am J Roentgenol. 1992;159(2):303–9.PubMed
14.
Zurück zum Zitat Jurisic D, Doko M, Glavan E, Rosko D, Vidovic D, Tomic K. Local recurrence of primary non-ampullary adenocarcinoma of duodenum after surgical treatment—a case report and a literature review. Coll Antropo. 2006;30(1):225–9. Jurisic D, Doko M, Glavan E, Rosko D, Vidovic D, Tomic K. Local recurrence of primary non-ampullary adenocarcinoma of duodenum after surgical treatment—a case report and a literature review. Coll Antropo. 2006;30(1):225–9.
15.
Zurück zum Zitat Santoro E, Sacchi M, Scutari F, Carboni F, Graziano F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology. 1997;44(16):1157–63.PubMed Santoro E, Sacchi M, Scutari F, Carboni F, Graziano F. Primary adenocarcinoma of the duodenum: treatment and survival in 89 patients. Hepatogastroenterology. 1997;44(16):1157–63.PubMed
16.
Zurück zum Zitat Bucher P, Gervaz P, Morel P. Long-term results of radical resection for locally advanced duodenal adenocarcinoma. Hepatogastroenterology. 2005;52(66):1727–9.PubMed Bucher P, Gervaz P, Morel P. Long-term results of radical resection for locally advanced duodenal adenocarcinoma. Hepatogastroenterology. 2005;52(66):1727–9.PubMed
17.
Zurück zum Zitat Stell D, Mayer D, Mirza D, Buckels J. Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum. Dig Surg. 2004;21(5–6):434–8.PubMedCrossRef Stell D, Mayer D, Mirza D, Buckels J. Delayed diagnosis and lower resection rate of adenocarcinoma of the distal duodenum. Dig Surg. 2004;21(5–6):434–8.PubMedCrossRef
18.
Zurück zum Zitat Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135(6):635–41.PubMedCrossRef Bakaeen FG, Murr MM, Sarr MG, Thompson GB, Farnell MB, Nagorney DM, et al. What prognostic factors are important in duodenal adenocarcinoma? Arch Surg. 2000;135(6):635–41.PubMedCrossRef
19.
Zurück zum Zitat Bal A, Joshi K, Vaiphei K, Wig JD. Primary duodenal neoplasms: a retrospective clinicopathological analysis. World J Gastroenterol. 2007;13(7):1108–11.PubMed Bal A, Joshi K, Vaiphei K, Wig JD. Primary duodenal neoplasms: a retrospective clinicopathological analysis. World J Gastroenterol. 2007;13(7):1108–11.PubMed
20.
Zurück zum Zitat Yang YM, Tian XD, Zhuang Y, Wang WH, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol. 2005;11(16):2456–61.PubMed Yang YM, Tian XD, Zhuang Y, Wang WH, Wan YL, Huang YT. Risk factors of pancreatic leakage after pancreaticoduodenectomy. World J Gastroenterol. 2005;11(16):2456–61.PubMed
21.
Zurück zum Zitat Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10(2):132–7.PubMedCrossRef Gibson MK, Holcroft CA, Kvols LK, Haller D. Phase II study of 5-fluorouracil, doxorubicin, and mitomycin C for metastatic small bowel adenocarcinoma. Oncologist. 2005;10(2):132–7.PubMedCrossRef
Metadaten
Titel
The Surgical Treatment and Outcome for Primary Duodenal Adenocarcinoma
verfasst von
Shao-Liang Han
Jun Cheng
Hong-Zhong Zhou
Qi-Qiang Zeng
Sheng-Hong Lan
Publikationsdatum
01.12.2010
Verlag
Springer US
Erschienen in
Journal of Gastrointestinal Cancer / Ausgabe 4/2010
Print ISSN: 1941-6628
Elektronische ISSN: 1941-6636
DOI
https://doi.org/10.1007/s12029-010-9160-1

Weitere Artikel der Ausgabe 4/2010

Journal of Gastrointestinal Cancer 4/2010 Zur Ausgabe

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Erhöhte Mortalität bei postpartalem Brustkrebs

07.05.2024 Mammakarzinom Nachrichten

Auch für Trägerinnen von BRCA-Varianten gilt: Erkranken sie fünf bis zehn Jahre nach der letzten Schwangerschaft an Brustkrebs, ist das Sterberisiko besonders hoch.

Hypertherme Chemotherapie bietet Chance auf Blasenerhalt

07.05.2024 Harnblasenkarzinom Nachrichten

Eine hypertherme intravesikale Chemotherapie mit Mitomycin kann für Patienten mit hochriskantem nicht muskelinvasivem Blasenkrebs eine Alternative zur radikalen Zystektomie darstellen. Kölner Urologen berichten über ihre Erfahrungen.

Ein Drittel der jungen Ärztinnen und Ärzte erwägt abzuwandern

07.05.2024 Klinik aktuell Nachrichten

Extreme Arbeitsverdichtung und kaum Supervision: Dr. Andrea Martini, Sprecherin des Bündnisses Junge Ärztinnen und Ärzte (BJÄ) über den Frust des ärztlichen Nachwuchses und die Vorteile des Rucksack-Modells.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.